Daewoong Pharmaceutical (069620) Stock Price, Fundamentals & Analysis

What 069620 does

Daewoong Pharmaceutical (069620) is a stock listed on the Korea Exchange in the Healthcare sector, specifically within the Drug Manufacturers – Specialty & Generic industry. The company develops, manufactures, and commercializes pharmaceutical products in South Korea and internationally, covering therapeutic areas such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound care, iron supplements, and multivitamins. It also provides medical devices including COVID-19 PCR kits, COVID-19 IgG/IgM rapid diagnostic tests, and viral transport media. Founded in 1945 and headquartered in Seoul, South Korea, it employs 1,893 people.

Key numbers explained

• The current price is 106,200 KRW, down 2.39% today.
• Its market capitalization is 1.22T KRW, representing the total market value of all outstanding shares.
• The forward P/E ratio of 6.3 divides the current price by expected future earnings, showing how the market values each unit of anticipated profit.
• The dividend yield is 0.56%, meaning the annual dividend represents 0.56% of the current share price.
• The ex-dividend date is 29 Dec 2025; buying before this date is typically required to receive the upcoming dividend.
• Only 4% of earnings is paid out as dividends, indicating the company retains most of its profit for reinvestment.
• The beta of 0.03 suggests the stock’s price movements have historically been much less volatile than the overall market.
• The 52-week range is 105,000 – 199,400 KRW, with the price down 21.6% over the past year.
• Trailing 12-month revenue is 1.64T KRW, growing 10.6% year over year.
• Profit margin is 12%, operating margin is 15.2%, and return on equity is 16.6%.
• The debt-to-equity ratio of 77.6% indicates the company uses a mix of debt and equity financing.

What to watch

• The healthcare sector and the Drug Manufacturers – Specialty & Generic industry are influenced by drug approval cycles, patent expirations, and regulatory changes in South Korea and international markets.
• Revenue growth of 10.6% and a profit margin of 12% reflect operational efficiency, but margins can shift with raw material costs and pricing pressure.
• The low beta of 0.03 suggests defensive characteristics, though it also means the stock may not participate strongly in broad market rallies.
• A debt-to-equity ratio of 77.6% is a factor to monitor, as it affects financial flexibility during interest rate changes or economic downturns.
• The dividend policy, with only 4% of earnings paid out, prioritizes reinvestment over income, which may appeal to growth-oriented investors.
• Peer companies such as Yuhan (000100), Hanall Biopharma (009420), and Celltrion (068270) operate in similar spaces and can provide context for relative performance.